Mechanistic biomarkers for cytotoxic acute kidney injury

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 5, 2006, Pages 697-713

  Vaidya, Vishal S ^a   Bonventre, Joseph V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute kidney injury; Acute renal failure; Biomarkers; Clusterin; CYR 61; Cystatin C; Cysteine rich protein 61; ELISA; IL 18; Kidney injury molecule 1; Kim 1; Microfluidics; Nanotechnology; Neutrophil gelatinase associated lipocalin; NGAL

Indexed keywords

BIOLOGICAL MARKER;

BODY FLUID; CYTOTOXICITY; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; PREVALENCE; REVIEW; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; RENAL INSUFFICIENCY, ACUTE;

ANIMALIA;

EID: 33846384296     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.5.697     Document Type: Review

References (206)

1. CHERTOW GM, LAZARUS JM, CHRISTIANSEN CL et al.: Preoperative renal risk stratification. Circulation (1997) 95(4):878-884.
2. THADHANI R, PASCUAL M, BONVENTRE JV: Acute renal failure. N. Engl. J. Med. (1996) 334(22):1448-1460.
3. HAN WK, BONVENTRE JV: Biologic markers for the early detection of acute kidney injury. Curr. Opin. Crit. Care (2004) 10(6):476-482.
4. STAR RA: Treatment of acute renal failure. Kidney Int. (1998) 54(6):1817-1831.
5. TOLKOFF-RUBIN NE, RUBIN RH, BONVENTRE JV: Noninvasive renal diagnostic studies. Clin. Lab. Med. (1988) 8(3):507-526.
6. PORTER GA, PALMER BF, HENRICH WL: Clinical Nephrotoxicants: Renal Injury from Drugs and Chemicals. DeBroe ME, Porter GA, Bennett WM, Verpooten GA (Eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (2003):3-20.
7. Challenge and opportunity on the critical path to new medical products (2004). White paper by FDA documenting that discovery of new predictive biomarkers is one of the solutions towards reducing drug development costs and improving outcomes in the clinical trials.
8. MEHTA RL, KELLUM JA, SHAH S et al.: AKIN: Acute Kidney Injury Network: report of an initiative. In: AKIN Summit. AKIN committee, Amsterdam, The Netherlands (2006). This is the first draft by the AKIN committee defining and classifying AKI to be used in clinical trials in patients with AKI.
9. WAIKAR SS, CURHAN GC, WALD R, MCCARTHY EP, CHERTOW GM: Declining mortality in patients with acute renal failure, 1988 to 2002. J. Am. Soc. Nephrol. (2006) 17(4):1143-1150.
10. PALEVSKY PM, MURRAY PT: Acute kidney injury and critical care nephrology. Nephrohgy Self-Assessment Program (2006) 5(2):72-120.
11. BELLOMO R, KELLUM JA, RONCO C: Defining acute renal failure: physiological principles. Intensive Care Med. (2004) 30(1):33-37.
12. BONVENTRE JV: Pathophysiology of ischemic acute renal failure. Inflammation, lung-kidney cross-talk, and biomarkers. Contrib. Nephrol. (2004) 144:19-30.
13. LAMEIRE N, HOSTE E: Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr. Opin. Crit. Care (2004) 10(6):468-475.
14. URAKAMI Y, KIMURA N, OKUDA M, INUI K: Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. (2004) 21(6):976-981.
15. URAKAMI Y, KIMURA N, OKUDA M et al.: Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab. Pharmacokinet. (2005) 20(3):200-205.
16. ALLGREN RL, MARBURY TC, RAHMAN SN et al.: Anaritide in acute tubule necrosis. Auriculun Anaritide Acute Renal Failure Study Group. N. Engl. J. Med. (1997) 336:828-834.
17. HIRSCHBERG R, KOPPLE J, LIPSETT P et al.: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. (1999) 55:2423-2432.
18. LEWIS J, SALEM MM, CHERTOW GM et al.: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am. J. Kidney Dis. (2000) 36(4):767-774.
19. WANG A, HOLCSLAW T, BASHORE TM et al.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. (2000) 57(4):1675-1680.
20. CHOUDHURY D, ZIAUDDIN A: Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol. (2005) 2(2):80-91.
21. KLEINKNECHT D, LANDAIS P, GOLDFARB B: Drug-associated acute renal failure. A prospective collaborative study of 81 biopsied patients. Adv. Exp. Med. Biol. (1987) 212:125-128.
22. MOSES H, 3RD, DORSEY ER, MATHESON DH, THIERSO: Financial anatomy of biomedical research. JAMA (2005) 294(11):1333-1342.
23. DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185.
24. WOODS JS: Urinary markers. In: Methods in Renal Toxicology. Lash LH (Ed.), CRC Press, Boca Raton, FL, USA (1996):19-33.
25. EMEIGH HART SG: Assessment of renal injury in vivo. J. Pharmacol. Toxicol. Methods (2005) 52(1):30-45.
26. USUDA K, KONO K, DOTE T et al.: Urinary biomarkers monitoring for experimental fluoride nephrotoxicity. Arch. Toxicol. (1998) 72(2):104-109.
27. WILEY RA, CHOO HY, TRAIGER GJ: The effect of nephrotoxic furans on urinary N-acetylglucosaminidase levels in mice. Toxicol. Lett. (1982) 14(1-2):93-96.
28. VAIDYA VS, SHANKAR K, LOCK EA, BUCCI TJ, MEHENDALE HM: Renal injury and repair following S-1, 2 dichlorovinyl-L-cysteine administration to mice. Toxicol. Appl. Pharmacol. (2003) 188(2):110-121.
29. LIU W, SCHOB O, PUGMIRE JE et al.: Glycohydrolases as markers of hepatic ischemia-reperfusion injury and recovery. Hepatology (1996) 24(1):157-162.
30. HUBANK M, SCHATZ DG: Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucl. Acid Res. (1994) 22:5640-5648.
31. ICHIMURA T, BONVENTRE JV, BAILLY V et al.: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. (1998) 273(7):4135-4142. This paper describes die identification and cloning of Kim-1 gene as a potential biomarker of AKI.
32. BAILLY V, ZHANG Z, MEIER W et al.: Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J. Biol. Chem. (2002) 277(42):39739-39748.
33. AMIN RP, VICKERS AE, SISTARE F et al.: Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. (2004) 112(4):465-479.
34. MCINTIRE JJ, UMETSU SE, AKBARI O et al.: Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. (2001) 2(12):1109-1116.
35. UMETSU SE, LEE WL, MCINTIRE JJ et al.: TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat. Immunol. (2005) 6(5):447-454.
36. MEYERS JH, SABATOS CA, CHAKRAVARTI S, KUCHROO VK: The TIM gene family regulates autoimmune and allergic diseases. Trends Mol. Med. (2005) 11(8):362-369.
37. ESPANDIARI P, MILLER T, ZHANG J et al.: Characterization of a rodent pediatric nephrotoxiciry model. Toxicologist (2006) 90(S1):25.
38. GOERING PL, VAIDYA VS, BROWN RP et al.: Kidney injury molecule-1 (kim-1) expression in kidney and urine following acute exposure to gentamicin and mercury. Toxicologist (2006) 90(S1):341.
39. HUMPHREYS BD, VAIDYA VS, SAMARAKOON R et al.: Early and sustained expression of kidney injury molecule-1 (Kim-1) after unilateral ureteral obstruction. J. Am. Soc. Nephrol. (2005) 16:425A.
40. ICHIMURA T, HUNG CC, YANG SA, STEVENS JL, BONVENTRE JV: Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol. (2004) 286(3):F552-F563.
41. KRAMER AB, VAN TIMMEREN MM, SCHUURS TA et al.: De novo induction of kidney injury molecule-1 (kim-1) in proteinuriainduced renal damage is reduced by raas blockade. Kidney Int. (2006) (Submitted).
42. PROZIALECK WC, VAIDYA VS, JOHNSON AM et al.: Kidney injury molecule-1 (kim-1) as an early biomarker of cadmium (cd) nephrotoxicity. Toxicologist (2006) 90(S1):340.
43. VAIDYA VS, RAMIREZ V, BOBADILLA NA, BONVENTRE JV: A microfluidics based assay to measure kidney injury molecule-1 (Kim-1) in the urine as a biomarker for early diagnosis of acute kidney injury. J. Am. Soc. Nephrol. (2005) 16:192A. This abstract demonstrates for the first time the use of microsphere-based technology for early detection and quantitation of Kim-1.
44. VAIDYA VS, RAMIREZ V, ICHIMURA T, BOBADILLA NA, BONVENTRE JV: Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. (2006) 290(2):F517-F529.
45. HAN WK, BAILLY V, ABICHANDANI R, THADHANI R, BONVENTRE JV: Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. (2002) 62:237-244.
46. MUKHERJEA D, WHITWORTH CA, NANDISH S et al.: Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience (2006) 139(2):733-740.
47. HAN WK, ALINANI A, WU CL et al.: Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. (2005) 16(4): 1126-1134.
48. KUEHN EW, PARK KM, SOMLO S, BONVENTRE JV: Kidney injury molecule-1 expression in murine polycystic kidney disease. Am. J. Physiol. Renal Physiol. (2002) 283(6):F1326-F1336.
49. TSUJI M, MONKAWA T, YOSHINO J et al.: Microarray analysis of a reversible model and an irreversible model of anti-Thy-1 nephritis. Kidney Int. (2006) 69(6):996-1004.
50. SCHUURS T, NIJBOER W, DAMMAN J et al.: Kidney injury molecule-1 (KIM-1) as an early marker for donor brain-death-associated renal injury. J. Am. Soc. Nephrol. (2005) 16:106A.
51. SCHUURS TA, GERBENS F, VAN DER HOEVEN JA et al.: Distinct transcriptional changes in donor kidneys upon brain death induction in rats: insights in the processes of brain death. Am. J. Transplant. (2004) 4(12):1972-1981.
52. VAN TIMMEREN MM, BAKKER SJ, VAIDYA versus et al.: Tubular kidney injury molecule-1 (Kim-1) in protein-overload nephropathy. Am. J. Physiol. Renal Physiol. (2006) 291(2):F456-F464.
53. BLASCHUK O, BURDZY K, FRITZ IB: Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. (1983) 258(12):7714-7720.
54. ROSENBERG ME, PALLER MS: Differential gene expression in the recovery from ischemic renal injury. Kidney Int. (1991) 39(6):1156-1161.
55. WlTZGALL R, BROWN D, SCHWARZ C, BONVENTRE JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J. Clin. Invest. (1994) 93(5):2175-2188.
56. KHARASCH ED, SCHROEDER JL, BAMMLER T, BEYER R, SRINOUANPRACHANH S: Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ('compound A') in rats. Toxicol. Sci. (2006) 90(2):419-431.
57. SILKENSEN JR, AGARWAL A, NATH KA, MANIVEL JC, ROSENBERG ME: Temporal induction of clusterin in cisplatin nephrotoxicity. J. Am. Soc. Nephrol. (1997) 8(2):302-305.
58. TSUCHIYA Y, TOMINAGA Y, MATSUBAYASHI K et al.: Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam. Arch. Toxicol. (2005) 79(9):500-507.
59. DAVIS JW II, GOODSAID FM, BRAL CM et al.: Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. (2004) 200(1):16-26.
60. BUTTYAN R, OLSSON CA, PINTAR J et al.: Induction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell. Biol. (1989) 9(8):3473-3481.
61. CHEVALIER RL: Growth factors and apoptosis in neonatal ureteral obstruction. J. Am. Soc. Nephrol. (1996) 7(8): 1098-1105.
62. CORREA-ROTTER R, HOSTETTER TH, MANIVEL JC, EDDY AA, ROSENBERG ME: Intrarenal distribution of clusterin following reduction of renal mass. Kidney Int. (1992) 41(4):938-950.
63. HARDING MA, CHADWICK LJ, GATTONE VH, 2ND, CALVET JP: The SGP-2 gene is developmentally regulated in the mouse kidney and abnormally expressed in collecting duct cysts in polycystic kidney disease. Dev. Biol. (1991) 146(2):483-490.
64. CORREA-ROTTER R, IBARRA-RUBIO ME, SCHWOCHAU G et al.: Induction of clusterin in tubules of nephroticrats. J. Am. Soc. Nephrol. (1998) 9(1):33-37.
65. DVERGSTEN J, MANIVEL JC, CORREA-ROTTER R, ROSENBERG ME: Expression of clusterin in human renal diseases. Kidney Int. (1994) 45(3):828-835.
66. SHANNAN B, SEIFERT M, LESKOV K et al.: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. (2000) 13(1):12-19.
67. AULITZKY WK, SCHLEGEL PN, WU DF et al.: Measurement of urinary clusterin as an index of nephrotoxicity. Proc. Soc. Exp. Biol. Med. (1992) 199(1):93-96.
68. ORLANDI A, PUCCI S, CIUCCI A et al.: Modulation of clusterin isoforms is associated with all-trans retinoic acid-induced proliferative arrest and apoptosis of intimal smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. (2005) 25(2):348-353.
69. CHEN X, HALBERG RB, EHRHARDT WM, TORREALBA J, DOVE WF: Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. USA (2003) 100(16):9530-9535.
70. NAKAMURA E, ABREU-E-LIMA P, AWAKURA Y et al.: Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am. J. Pathol. (2006) 168(2):574-584.
71. PUCCIS, BONANNO E, PICHIORRI F, ANGELONI C, SPAGNOLI LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene (2004) 23(13):2298-2304.
72. COWLAND JB, SORENSEN OE, SEHESTED M, BORREGAARD N: Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J. Immunol. (2003) 171(12):6630-6639.
73. NIELSEN BS, BORREGAARD N, BUNDGAARD JR et al.: Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut (1996) 38(3):414-420.
74. MATTHAEUS T, ICHIMURA T, WEBER M, ANDREUCCI M, PARK KM, BONVENTRE JV: Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney. J. Am. Soc. Nephrol. (2001) 12:787A.
75. MISHRA J, MA Q, PRADA A et al.: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. (2003) 14(10):2534-2543.
76. MISHRA J, MORI K, MA Q et al.: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. (2004) 24(3):307-315.
77. MORI K, LEE HT, RAPOPORT D et al.: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. (2005) 115(3):610-621.
78. MISHRA J, DENT C, TARABISHI R et al.: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 365(9466):1231-1238. This paper documents that high levels of urinary NGAL predics the onset of AKI 2 h after cardiopulmonary bypass in children undergoing cardiac surgery, 2 - 4 days before AKI was identified by changes in serum creatinine.
79. MISHRA J, MA Q, KELLY C, MITSNEFES M, DEVARAJAN P: Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr. Nephrol. (2006) 21(6):856-863.
80. FLOWER DR, NORTH AC, SANSOM CE: The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta (2000) 1482(1-2):9-24.
81. YANG J, GOETZ D, LI JY et al.: An iron delivery pathway mediated by a lipocalin. Mol. Cell (2002) 10(5):1045-1056.
82. BERGER T, TOGAWA A, DUNCAN GS et al.: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA (2006) 103(6):1834-1839.
83. FRIEDL A, STOESZ SP, BUCKLEY P, GOULD MN: Neutrophil gelatinase- associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. (1999) 31(7):433-441.
84. FURUTANI M, ARII S, MIZUMOTO M, KATO M, IMAMURA M: Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. (1998) 122(1-2):209-214.
85. FERNANDEZ CA, YAN L, LOUIS G et al.: The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. (2005) 11(15):5390-5395.
86. FILLER G, BOKENKAMP A, HOFMANN W et al.: Cystatin C as a marker of GFR-history, indications, and future research. Clin. Biochem. (2005) 38(1):1-8.
87. JANOWSKI R, KOZAK M, JANKOWSKA E et al.: Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. (2001) 8(4):316-320.
88. STAR R, HOSTETTER T, HORTIN GL: New markers for kidney disease. Clin. Chem. (2002) 48(9):1375-1376.
89. NEWMAN DJ, THAKKAR H, EDWARDS RG et al.: Serum q-statin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. (1995) 47(0:312-318.
90. HERGET-ROSENTHAL S, MARGGRAF G, HUSING J et al.: Early detection of acute renal failure by serum cystatin C. Kidney Int. (2004) 66(3):1115-1122.
91. HERGET-ROSENTHAL S, PIETRUCK F, VOLBRACHT L, PHILIPP T, KRIBBEN A: Serum cystatin C - a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin. Nephrol. (2005) 64(1):41-46.
92. VOSKARIDOU E, TERPOS E, MICHAIL S et al.: Early markers of renal dysfunction in patients with sickle cell/β-thalassemia. Kidney Int. (2006).
93. BOKENKAMP A, CIARIMBOLI G, DIETERICH C: Cystatin C in a rat model of end-stage renal failure. Ren. Fail. (2001) 23(3-4):431-438.
94. KYHSE-ANDERSENJ1SCHMIDTC, NORDIN G et al.: Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. (1994) 40(10):1921-1926.
95. CONTI M, MOUTEREAU S, ZATER M et al.: Urinary q-statin C as a specific marker of tubular dysfunction. Clin. Chem. Lab. Med. (2006) 44(3):288-291.
96. VRAY B, HARTMANN S, HOEBEKE J: Immunomodulatory properties of cystatins. Cell. Mol. Life Sci. (2002) 59(9):1503-1512.
97. YANO M, HIRAI K, NAITO Z et al.: Expression of cathepsin B and cystatin C in human breast cancer. Surg. Today (2001) 31(5):385-389.
98. SALEH Y, SEBZDA T, WARWAS M et al.: Expression of cystatin C in clinical human colorectal cancer tissues. J. Exp. Ther. Oncol. (2005) 5(1):49-53.
99. SOKOL JP, NEIL JR, SCHIEMANN BJ, SCHIEMANN WP: The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-β. Breast Cancer Res. (2005) 7(5):R844-R853.
100. YANG GP, LAU LF: Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. (1991) 2(7):351-357.
101. PERBAL B: The CCN family of genes: a brief history. Mol. Pathol. (2001) 54(2): 103-104.
102. TSAI MS, HORNBY AE, LAKINS J, LUPU R: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. (2000) 60(20):5603-5607.
103. MURAMATSU Y, TSUJIE M, KOHDA Y et al.: Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic-reperfusion injury. Kidney Int. (2002) 62(5):1601-1610.
104. NAKAMURA K, OKAMURA H, NAGATA K, KOMATSU T, TAMURA T: Purification of a factor which provides a costimulatory signal for γ interferon production. Infect. Immun. (1993) 61(1):64-70.
105. PARIKH CR, JANI A, MELNIKOV VY, FAUBEL S, EDELSTEIN CL: Urinary interleukin-18 is a marker of human acute tubular necrosis. Am. J. Kidney Dis. (2004) 43(3):405-414.
106. PARIKH CR, ABRAHAM E, ANCUKIEWICZ M, EDELSTEIN CL: Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J. Am. Soc. Nepbrol. (2005) 16(10):3046-3052.
107. MELNIKOV VY, ECDER T, FANTUZZI G et al.: Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. (2001) 107(9):1145-1152.
108. SUGAWARA I: Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect. (2000) 2(10):1257-1263.
109. OKAMURA H, TSUTSI H, KOMATSU T et al.: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature (1995) 378(6552):88-91.
110. DAO T, OHASHI K, KAYANO T, KURIMOTO M, OKAMURA H: Interferon-γ- inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. (1996) 173(2):230-235.
111. UDAGAWA N, HORWOOD NJ, ELLIOTT J et al.: Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. (1997) 185(6):1005-1012.
112. FUKUMOTO H, NISHIO M, NISHIO K et al.: Interferon-γ-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn. J. Cancer Res. (1997) 88(5):501-505.
113. PARK CC, MOREL JC, AMIN MA et al.: Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. (2001) 167(3): 1644-1653.
114. OHTSUKI T, MICALLEF MJ, KOHNO K et al.: Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anti-Cancer Res. (1997) 17(5A):3253-3258.
115. GUNEL N, COSKUN U, SANCAK B et al.: Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am. J. Clin. Oncol. (2003) 26(4):416-421.
116. PAGES F, BERGER A, HENGLEIN B et al.: Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer (1999) 84(3):326-330.
117. KAWABATA T, ICHIKURA T, MAJIMA T et al.: Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer (2001) 92(8):2050-2055.
118. TAKUBO T, KUMURA T, NAKAO T et al.: Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol. (2000) 104(4):220-222.
119. XIE Y, SAKATSUME M, NISHI S et al.: Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. (2001) 60(5):1645-1657.
120. HUDKINS KL, GIACHELLI CM, CUI Y et al.: Osteopontin expression in fetal and mature human kidney. J. Am. Soc. Nephrol. (1999) 10(3):444-457.
121. THOMAS SE, LOMBARDI D, GIACHELLI C, BOHLE A, JOHNSON RJ: Osteopontin expression, tubulointerstitial disease, and essential hypertension. Am. J. Hypertens. (1998) 11(8 Pr 1):954-961.
122. MEZZANO SA, DROGUETT MA, BURGOS ME et al.: Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int. (2000) 57(1):147-158.
123. HUDKINS KL, GIACHELLI CM, EITNER F et al.: Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. (2000) 57(1):105-116.
124. OKADA H, MORIWAKI K, KONISHI K et al.: Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am. J. Kidney Dis. (2000) 36(3):498-506.
125. HUDKINS KL, LE QC, SEGERER S et al.: Osteopontin expression in human cyclosporine toxicity. Kidney Int. (2001) 60(2):635-640.
126. ALCHI B, NISHI S, KONDO D et al.: Osteopontin expression in acute renal allograft rejection. Kidney Int. (2005) 67(3):886-896.
127. GANG X, UEKI K, KON S et al.: Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am. J. Kidney Dis. (2001) 37(2):374-379.
128. MIN W, SHIRAGA H, CHALKO C et al.: Quantitative studies of human urinary excretion of uropontin. Kidney Int. (1998) 53(1):189-193.
129. ASPLIN JR, ARSENAULT D, PARKS JH, COE FL, HOYER JR: Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. (1998) 53(1):194-199.
130. BONVINI JM, SCHATZMANN U, BECK-SCHIMMER B et al.: Lack of in vivo function of osteopontin in experimental anti-GBM nephritis. J. Am. Soc. Nephrol. (2000) 11(9):1647-1655.
131. LIAW I., BIRK DE, BALLAS CB et al.: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. (1998) 101(7):1468-1478.
132. CHAMBERS AF, VANDERHYDEN BC: Ovarian cancer biomarkers in urine. Clin. Cancer Res. (2006) 12(2):323-327.
133. GLATZ JF, VAN DER VUSSE GJ: Cellular fatty acid-binding proteins: their function and physiological significance. Prog. Lipid Res. (1996) 35(3):243-282.
134. PELSERS MM, HERMENS WT, GLATZ JF: Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chim. Acta (2005) 352(1-2):15-35.
135. LAM KT, BORKAN S, CLAFFEY KP et al.: Properties and differential regulation of two fatty acid binding proteins in the rat kidney. J. Biol. Chem. (1988) 263(30):15762-15768.
136. SCHAAP FG, VAN DER VUSSE GJ, GLATZ JF: Evolution of the family of intracellular lipid binding proteins in vertebrates. Mol. Cell. Biochem. (2002) 239(1-2):69-77.
137. MAATMAN RG, VANKUPPEVELT TH, VEERKAMP JH: Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem. J. (1991) 273(Pt 3):759-766.
138. SWEETSER DA, HEUCKEROTH RO, GORDON JI: The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Ann. Rev. Nutr. (1987) 7:337-359.
139. PELSERS MM, DAVIES D: Fatty acid binding protein: a new biomarker of nephrotoxicity in the rat (abstract). 4th international conference on lipid binding proteins. Maastricht, The Netherlands (2001).
140. KAMIJO A, KIMURA K, SUGAYA T et al.: Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J. Lab. Clin. Med. (2004) 143(1):23-30.
141. KAMIJO A, SUGAYA T, HIKAWA A et al.: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Cell. Biochem. (2006) 284(1-2):175-182.
142. KAMIJO A, SUGAYA T, HIKAWA A et al.: Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am. J. Pathol. (2004) 165(4):1243-1255.
143. YOUNG AC, SCAPIN G, KROMMINGA A et al.: Structural studies on human muscle fatty acid binding protein at 1.4 A resolution: binding interactions with three C18 fatty acids. Structure (1994) 2(6):523-534.
144. KIMURA H, FUJII H, SUZUKI S et al.: Lipid-binding proteins in rat and human kidney. Kidney Int. Suppl. (1999) 71:S159-S162.
145. MAIR J: Progress in myocardial damage detection: new biochemical markers for clinicians. Crit. Rev. Clin. Lab. Sci. (1997) 34(1):1-66.
146. PISITKUN T, SHEN RF, KNEPPER MA: Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA (2004) 101(36):13368-13373.
147. + exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am. J. Kidney Dis. (2003) 42(3):497-506.
148. SCHWARTZ N, HOSFORD M, SANDOVAL RM et al.: Ischemia activates actin depolymerizing factor: role in proximal tubule microvillar actin alterations. Am. J. Physiol. (1999) 276(4 Pt 2):F544-F551.
149. TARABISHI R, ZAHEDI K, MISHRA J et al.: Induction of Zf9 in the kidney following early ischemia/reperfusion. Kidney Int. (2005) 68(4):1511-1519.
150. ZHANG H, CHENG X, RICHTER M, GREENE MI: A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat. Med. (2006) 12(4):473-477. This paper reports a T7 RNA polymerase-based method to increase the sensitivity of ELISAs.
151. CARSON RT, VIGNALI DA: Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods (1999) 227(1-2):41-52.
152. VIGNALI DA: Multiplexed particle-based flow cytometric assays. J. Immunol. Methods (2000) 243(1-2):243-255.
153. HU H, AIZENSTEIN BD, PUCHALSKI A et al.: Elevation of CXCR3-bindingchemokines in urine indicates acute renal-allograft dysfunction. Am. J. Transplant. (2004) 4(3):432-437.
154. OLSSON A, VANDERSTICHELE H, ANDREASEN N et al.: Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. (2005) 51(2):336-345.
155. WANG WU, CHEN C, LIN KH, FANG Y, LIEBER CM: Label-free detection of small-molecule-protein interactions by using nanowire nanosensors. Proc. Natl. Acad. Sci. USA (2005) 102(9):3208-3212.
156. ZHENG G, PATOLSKY F, CUI Y, WANG WU, LIEBER CM: Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. (2005) 23(10):1294-1301. This paper reports the development and use of a nanowire sensor array to quantitate multiple biomarkers using the basic principle of change in conductance based on antigen-antibody interaction.
157. BENNETT WM, BURDMANN EA, ANDOH TF et al.: Nephrotoxicity of immunosuppressive drugs. Nephrol. Dial. Transplant. (1994) 9(Suppl. 4):141-145.
158. BURDMANN EA, ANDOH TF, LINDSLEY J et al.: Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Ren. Fail. (1994) 16(1):161-168.
159. CHAPELSKY MC, NIX DE, CAVANAUGH JC et al: Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers. Drug Saf. (1992) 7(4):304-309.
160. GHAZNAVI R, FAGHIHI M, KADKHODAEE M, SHAMS S, KHASTAR H: Effects of nitric oxide on gentamicin toxicity in isolated perfused rat kidneys. J. Nephrol. (2005) 8(5):548-552.
161. DAVIES SJ, REICHARDT-PASCAL SY, VAUGHAN D, RUSSELL GI: Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp. Nephrol. (1995) 3(6):348-354.
162. HARRISON DJ, KHARBANDA R, BISHOP D, MCLELLAND LI, HAYES JD: Glutathione S-transferase isoenzymes in human renal carcinoma demonstrated by immunohistochemistry. Carcinogenesis (1989) 10(7):1257-1260.
163. FEINFELD DA, FLEISCHNER GM, ARIAS IM: Urinary ligandin and glutathione-5-transferase in gentamicin-induced nephrotoxicity in the rat. Clin. Sci. (Lond) (1981) 61(1):123-125.
164. CHUANG ST, CHU P, SUGIMURA J et al.: Overexpression of glutathione 5-transferase α in clear cell renal cell carcinoma. Am. J. Clin. Pathol. (2005) 123(3):421-429.
165. CLEMO FA: Urinary enzyme evaluation of nephrotoxicity in the dog. Toxicol. Pathol. (1998) 26(1):29-32.
166. MARUHN D, STROZYK K, GIELOW L, BOCK KD: Diurnal variations of urinary enzyme excretion. Clin. Chim. Acta (1977) 75(3):427-433.
167. CUTRIN JC, ZINGARO B, CAMANDOLA S et al.: Contribution of gamma glutamyl transpeptidase to oxidative damage of ischemic rat kidney. Kidney Int. (2000) 57(2):526-533.
168. PARSONS PP, GARLAND HO, HARPUR ES, OLD S: Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. Br. J. Pharmacol. (1997) 122(3):570-576.
169. GIROLAMI JP, BASCANDS JL, PECHER C et al.: Renal kallikrein excretion as a distal nephrotoxicity marker during cadmium exposure in rats. Toxicology (1989) 55(1-2):117-129.
170. GIROLAMI JP, ORFILA C, CABOS-BOUTOT G et al.: Early acute effects of mercuric chloride on synthesis and release of kallikrein and on distal tubular morphology of rat renal cortical slices. Ren. Physiol. Biochem. (1990) 13(4):223-232.
171. CARDENAS A, ROELS H, BERNARD AM et al.: Markers of early renal changes induced by industrial pollutants. I. Application to workers exposed to mercury vapour. Br. J. Ind. Med. (1993) 50(1):17-27.
172. ROELS H, BERNARD AM, CARDENAS A et al.: Markers of early renal changes induced by industrial pollutants. III. Application to workers exposed to cadmium. Br. J. Ind. J. Med. (1993) 50(1):37-48.
173. WANG X, QIN Q, XU X et al.: Chromium-induced early changes in renal function among ferrochromium-producing workers. Toxicology (1994) 90(1-2):93-101.
174. ZAGER RA, TEUBNER EJ, ADLER S: Low molecular weight proteinuria exacerbates experimental ischemic renal injury. Lab. Invest. (1987) 56(2):180-188.
175. HOUSER MT, BERNDT WO: The effect of unilateral nephrectomy on the nephrotoxicity of mercuric chloride in the rat. Toxicol. Appl. Pharmacol. (1986) 83(3):506-515.
176. HEMMINGSEN L, SKAARUP P: Urinary excretion often plasma proteins in patients with febrile diseases. Acta Med. Scand. (1977) 201(4):359-3G4.
177. LINDQUIST J, DRUECK C, SIMON NM et al.: Proximal renal tubular dysfunction in severe burns. Am. J. Kidney Dis. (1984) 4(1):44-47.
178. WILAND P, SZECHCINSKI J: Proximal tubule damage in patients treated with gentamicin or amikacin. Pol. J. Pharmacol. (2003) 55(4):631-637.
179. BRZOSKA MM, KAMINSKI M, SUPERNAK-BOBKO D, ZWIERZ K, MONIUSZKO-JAKONIUK J: Changes in the structure and function of the kidney of rats chronically exposed to cadmium. I. Biochemical and histopathological studies. Arch. Toxicol. (2003) 77(6):344-352.
180. HAMADA Y, KANDA T, ANZAI T, KOBAYASHI I, MORISHITA Y: N-acetyl-β-D-glucosaminidase is not a predictor, but an indicator of kidney injury in patients with cardiac surgery. J. Med. (1999) 30(5-6):329-336.
181. LIU J, LIU Y, HABEEBU SM, WAALKES MP, KLAASSEN CD: Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. Toxicology (2000) 147(3): 157-166.
182. VLASKOU D, HOFMANN W, GUDER WG, SISKOS PA, DIONYSSIOU-ASTERIOU A: Human neutral brush border endopeptidase EC 3.4.24.11 in urine, its isolation, characterisation and activity in renal diseases. Clin. Chim. Acta (2000) 297(1-2):103-121.
183. LEBEAU C, DEBELLE FD, ARLT VM et al.: Early proximal tubule injury in experimental aristolochic acid nephropathy. functional and histological studies. Nephrol. Dial. Transplant. (2005) 20(11):2321-2332.
184. 2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. (2005) 5(4 Pt 1):729-738.
185. FELS LM, BUNDSCHUH I, GWINNER W et al.: Early urinary markers of target nephron segments as studied in cadmium toxicity. Kidney Int. Suppl. (1994) 47:S81-S88.
186. AOYAGI T, HAYAKAWA K, MIYAJI K, ISHIKAWA H, HATA M: Cadmium nephrotoxicity and evacuation from the body in a rat modeled subchronic intoxication. Int. J. Urol. (2003) 10(6):332-338.
187. BERNARD AM, VYSKOCIL AA, MAHIEU P, LAUWERYS RR: Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin. Chem. (1987) 33(6):775-779.
188. MUTTI A, COCCINI T, ALINOVI R et al.: Exposure to hydrocarbons and renal disease: an experimental animal model. Ren. Fail. (1999) 21(3-4):369-385.
189. GENGOUX P, LACHAPELLE JM, MONTPLAISIR S, PELLETIER M: Significance of renal brush border antibodies in skin immune complex-related diseases. Arch. Dermatol. Res. (1981) 270(2): 175-178.
190. BERGAMASCHI E, MUTTI A, BOCCHI MC et al.: Rat model of perchloroethylene-induced renal dysfunctions. Environ. Res. (1992) 59(2):427-439.
191. BLOUIN P, GUIOT MC, JOTHY S: Definition of the human renal cell carcinoma phenotype using monoclonal and polyclonal antibodies: a tumor marker study. Exp. Pathol. (1989) 36(3):147-163.
192. BASU TK, ROWLANDS L, JONES L, KOHN J: Vitamin A and retinol-binding protein in patients with myelomatosis and cancer of epithelial origin. Eur. J. Cancer Clin. Oncol. (1982) 18(4):339-342.
193. HIDAKA S, KRANZLIN B, GRETZ N, WITZGALL R: Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. (2002) 310(3):289-296.
194. ODA H, SHIINA Y, SEIKI K et al.: Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin. Chem. (2002)48(9):1445-1453.
195. MENENDEZ JA, MEHMI I, GRIGGS DW, LUPU R: The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr. Relat. Cancer (2003) 10(2):141-152.
196. DAEMEN MA, VAN'T VEER C, WOLFS TG, BUURMAN WA: Ischemia/reperfusion- induced IFN-γ up-regulation: involvement of IL-12 and IL-18. J. Immunol. (1999) 162(9):5506-5510.
197. CHAN ED, CHOI HS, COOL C, ACCURSO FJ, FANTUZZI G: Interleukin-18 expression in cystic fibrosis lungs. Chest (2002) 121(3 Suppl.):84S-85S.
198. HOMSI E, JANINO P, DE FARIA JB: Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int. (2006) 69(8):1385-1392.
199. SOZEN S, COSKUN U, SANCAK B et al.: Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma (2004) 51(1):25-29.
200. RAO VS, DYER CE, JAMEEL JK, DREW PJ, GREENMAN J: Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol. Rep. (2006) 15(1):179-185.
201. KLEINMAN JG, WORCESTER EM. BESHENSKY AM et al.: Upregulation of osteopontin expression by ischemia in rat kidney. Ann. NY Acad. Sci. (1995) 760:321-323.
202. TUCK AB, CHAMBERS AF: The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia (2001) 6(4):419-429.
203. KWON O, MOLITORIS BA, PESCOVITZ M, KELLY KJ: Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am. J. Kidney Dis. (2003) 41(5):1074-1087.
204. SABOLIC I, HERAK-KRAMBERGER CM, LJUBOJEVIC M, BIEMESDERFER D, BROWN D: NHE3 and NHERF are targeted to the basolateral membrane in proximal tubules of colchicine-treated rats. Kidney Int. (2002) 61(4):1351-1364.
205. LAJER H, KRISTENSEN M, HANSEN HH et al.: Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother. Pharmacol. (2005) 56(5):535-542.
206. PEREZ-ROJAS J, BLANCO JA, CRUZ C et al.: Mineralocorticoid receptor blocade confers renoprotection in existing chronic cyclosporine nephrotoxicity. Am. J. Physiol. Renal Physiol. (2006) (In Press).